BR112021026852A2 - Sialidases recombinantes e métodos de uso das mesmas - Google Patents

Sialidases recombinantes e métodos de uso das mesmas

Info

Publication number
BR112021026852A2
BR112021026852A2 BR112021026852A BR112021026852A BR112021026852A2 BR 112021026852 A2 BR112021026852 A2 BR 112021026852A2 BR 112021026852 A BR112021026852 A BR 112021026852A BR 112021026852 A BR112021026852 A BR 112021026852A BR 112021026852 A2 BR112021026852 A2 BR 112021026852A2
Authority
BR
Brazil
Prior art keywords
methods
sialidases
recombinant
recombinant sialidases
prolonging
Prior art date
Application number
BR112021026852A
Other languages
English (en)
Inventor
Abhishek Das
S Turner Andrew
W Broderick James
D Normington Karl
Li Peng
Lihui Xu
Lizhi Cao
A Shelke Sandip
B Nerle Sujata
C Gatlin Wayne
B Siddiquee Zakir
Original Assignee
Palleon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palleon Pharmaceuticals Inc filed Critical Palleon Pharmaceuticals Inc
Publication of BR112021026852A2 publication Critical patent/BR112021026852A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

sialidases recombinantes e métodos de uso das mesmas. a presente invenção refere-se, em geral, a sialidases recombinantes, métodos e composições para prolongar a meia-vida sérica das sialidases recombinantes e uso das mesmas no tratamento de um distúrbio relacionado ao ácido siálico.
BR112021026852A 2019-07-03 2020-07-03 Sialidases recombinantes e métodos de uso das mesmas BR112021026852A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870336P 2019-07-03 2019-07-03
US202062957027P 2020-01-03 2020-01-03
PCT/US2020/040827 WO2021003468A2 (en) 2019-07-03 2020-07-03 Recombinant sialidases and methods of using the same

Publications (1)

Publication Number Publication Date
BR112021026852A2 true BR112021026852A2 (pt) 2022-02-22

Family

ID=74100201

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021026852A BR112021026852A2 (pt) 2019-07-03 2020-07-03 Sialidases recombinantes e métodos de uso das mesmas

Country Status (11)

Country Link
US (1) US20220362351A1 (pt)
EP (1) EP3994271A4 (pt)
JP (1) JP2022538895A (pt)
KR (1) KR20220034812A (pt)
CN (1) CN114269937A (pt)
AU (1) AU2020300680A1 (pt)
BR (1) BR112021026852A2 (pt)
CA (1) CA3145772A1 (pt)
IL (1) IL289431A (pt)
MX (1) MX2022000032A (pt)
WO (1) WO2021003468A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136167A1 (en) 2018-01-03 2019-07-11 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512710B2 (en) * 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
WO2017123745A1 (en) * 2016-01-12 2017-07-20 Palleon Pharma Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
ES2947312T3 (es) * 2016-07-01 2023-08-04 Univ Leland Stanford Junior Conjugados para la edición dirigida de la superficie celular
WO2019136167A1 (en) * 2018-01-03 2019-07-11 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
EP3906096A4 (en) * 2019-01-03 2023-03-01 Palleon Pharmaceuticals Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH IMMUNE CELLS
CA3145676A1 (en) * 2019-07-03 2021-01-07 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same

Also Published As

Publication number Publication date
IL289431A (en) 2022-02-01
MX2022000032A (es) 2022-06-15
AU2020300680A1 (en) 2022-02-03
WO2021003468A3 (en) 2021-02-11
JP2022538895A (ja) 2022-09-06
EP3994271A4 (en) 2023-07-19
EP3994271A2 (en) 2022-05-11
KR20220034812A (ko) 2022-03-18
CA3145772A1 (en) 2021-01-07
US20220362351A1 (en) 2022-11-17
WO2021003468A2 (en) 2021-01-07
CN114269937A (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
CL2022003763A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MY194175A (en) Variant rnai
PE20170140A1 (es) Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer
MX2022007968A (es) Dosificacion de gamma-hidroxibutirato (ghb).
PH12019550076A1 (en) SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
BR112021024978A2 (pt) Composições engajadoras específicas para macrófagos e métodos de uso das mesmas
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
BR112021025645A2 (pt) Degradação de proteína alvo de parp14 para uso em terapia
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
MX2021007848A (es) Proteinas de union a anti-ctla-4 y metodos de uso de las mismas.
BR112022011902A2 (pt) Terapias de combinação
WO2019157495A3 (en) Methods for preventing and/or treating bone loss conditions by modulating irisin
UY38503A (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
BR112021026852A2 (pt) Sialidases recombinantes e métodos de uso das mesmas
EA202290001A1 (ru) Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута
MX2021003298A (es) Métodos para revertir la actividad ticagrelor.
BR112016008086A2 (pt) Glicoproteínas recombinantes e usos das mesmas
BR112018001391A2 (pt) terapias de combinação